Remission Induction of Very Early Rheumatoid Arthritis with Methotrexate and Etanercept

Remission Induction of Very Early Rheumatoid Arthritis with Methotrexate and Etanercept - RIVERAME

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000452

Enrollment

Registered

2006-08-01

Start date

2006-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

methotrexate 8mg/week methotrexate 8mg/week and etanercept(25mg x1-2/week) for 3 months methotrexate 8mg/week and etanercept(25mgx1-2/week) for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with reheumatoid arthritis who satisfiy the 1987 ACR criteria(within one year from the onset),show DAS28 more than 3.2 and give inforted consent in a witten form

Exclusion criteria

Exclusion criteria: patients who are contra indicated for methotrexate or etanercept

Design outcomes

Primary

Measure	Time frame
Inhibitiion of joint destruction as shown by Sharp score, Knee joint X-ray, and serum MMP3 levels, and remission rates evaluated by DAS28	—

Countries

Japan

Contacts

Public ContactShunsei Hirohata

Teikyo University School of Medicine Department of Internal Medicine

shun-tei@umin.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026